Pipeline
Dr. Michael Weiss has recently invented, synthesized, tested, and applied for patents on more than 80 novel insulin analogs. Of those, Thermalin currently has identifed both short-acting and long-acting lead compounds.
Ultra-Rapid Acting Insulins
Taken before meals to dampen glucose spikes, currently available short-acting insulins analogs have shortcomings that include less than optimal onset and a post-meal "tail" which can lead to hypoglycemia and weight gain.
Thermalin's rapid-acting insulins are expected to address many of these deficiencies by providing several benefits including:
Thermalin's rapid-acting insulins are expected to address many of these deficiencies by providing several benefits including:
> Can be injected closer to meals
> Reduced post-meal side-effects
> Less weight gain
> Do not need tobe refrigerated
> Enhanced health of insulin-producing cells
> Lower cancer risk
> Finer glucose control by next generation, closed-loop pumps
> Reduced clogging of insulin pumps
> Reduced post-meal side-effects
> Less weight gain
> Do not need tobe refrigerated
> Enhanced health of insulin-producing cells
> Lower cancer risk
> Finer glucose control by next generation, closed-loop pumps
> Reduced clogging of insulin pumps
Long Acting Insulins
A base-level of insulin is present throughout the day in the blood of healthy individuals. Long-acting insulin, commonly injected once or twice daily, is meant to promote this non-mealtime, basal level in diabetes patients. Unfortunately, existing basal insulin has been associated with elevated cancer risk.
Thermalin is developing long-acting compounds which are expected to greatly improve basal insulin treatment. Potential benefits include:
Thermalin is developing long-acting compounds which are expected to greatly improve basal insulin treatment. Potential benefits include:
> Full 24-hour release profile
> Lower cancer risk
> Tunable kinetics
> Lower cancer risk
> Tunable kinetics
